NCT00764777已完成4 期
Physician Initiated Multi-center Belgian-Italian-Dutch Trial Investigating Abbott Vascular Iliac Stents in the Treatment of TASC A, B, C & D Iliac Lesions
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 325
- 试验地点
- 9
- 主要终点
- Primary patency defined as a target lesion without a hemodynamically significant stenosis on duplex ultrasound (>50%, systolic velocity ratio no greater than 2.0) and without TLR
研究概览
简要总结
The BRAVISSIMO trial wants to investigate in a controlled setting, the long-term (up to 24 months) outcome of the self-expanding nitinol Absolute Pro (Abbott Vascular) and the balloon-expandable Omnilink Elite (Abbott Vascular) stent in TASC A&B and TASC C&D iliac lesions. A separate analysis of both patient populations will be performed and listed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient presenting with a stenotic or occlusive lesion at the iliac arteries suitable for stenting (on indication for primary stenting, based on the discretion of the investigator)
- •Patient presenting a score from 2 to 5 following Rutherford classification
- •Patient is willing to comply with specified follow-up evaluations at the specified times for the duration of the study
- •Patient is >18 years old
- •Patient (or their legal representative) understands the nature of the procedure and provides written informed consent, prior to enrolment in the study
- •Patient is eligible for treatment with the Absolute Pro or Omnilink Elite (Abbott Vascular)
- •ANGIOGRAPHIC
- •The target lesion is either a modified TASC-II class A, B, C or D lesion with one of the listed specifications:
- •Type A lesions
- •Unilateral or bilateral stenoses of the Common Iliac Artery
- •Unilateral or bilateral single short (≤3 cm) stenosis of the External Iliac Artery
- •Type B lesions
- •Unilateral Common Iliac Artery occlusion
- •Single or multiple stenosis totaling 3-10 cm involving the External Iliac Artery not extending into the Common Femoral Artery
- •Unilateral External Iliac Artery occlusion not involving the origins of Internal Iliac Artery or Common Iliac Artery
- •Type C lesions
- •Bilateral Common Iliac Artery occlusions
- •Bilateral External Iliac Artery stenoses 3-10 cm long not extending into the Common Femoral Artery
- •Unilateral External Iliac Artery stenosis extending into the Common Femoral Artery
- •Unilateral External Iliac Artery occlusion that involves the origins of the Internal Iliac and/or Common Femoral Artery
- •Heavily calcified unilateral External Iliac Artery occlusion with or without involvement of origins of the Internal Iliac and/or Common Femoral Artery
- •Type D lesions
- •Unilateral occlusions of both Common Iliac and External Iliac Artery
- •Diffuse disease involving the aorta and both iliac arteries requiring treatment
- •Diffuse multiple stenoses involving the unilateral Common Iliac, External Iliac and Common Femoral Artery
- •Bilateral occlusions of External Iliac Artery
- •The target lesion has angiographic evidence of stenosis or restenosis > 50% or occlusion which can be passed with standard guidewire manipulation
- •There is angiographic evidence of a patent Common an Deep Femoral Artery
排除标准
- •The target lesion is either a modified TASC-II class B or D lesion with aortic lesion involvement:
- •Type B lesions
- •Short (≤3 cm) stenosis of infrarenal aorta
- •Type D lesions
- •Infra-renal aortoiliac occlusion
- •Iliac stenoses in patients with an Abdominal Aortic Aneurysm (AAA) requiring treatment and not amenable to endograft placement or other lesions requiring open aortic or iliac surgery
- •Presence of aneurysm at the level of the iliac arteries
- •Previously implanted stent(s) at the same lesion site
- •Reference segment diameter is not suitable for available stent design
- •Untreatable lesion located at the distal outflow arteries
- •Use of alternative therapy (e.g. atherectomy, cutting balloon, laser, radiation therapy) as part of the index procedure
- •Patients refusing treatment
- •Patients for whom antiplatelet therapy, anticoagulants or thrombolytic drugs are contraindicated
- •Patients who exhibit persistent acute intraluminal thrombus of the proposed lesion site
- •Perforation at the angioplasty site evidenced by extravasation of contrast medium
- •Patients with a history of prior life-threatening contrast medium reaction
- •Patients with known hypersensitivity to nickel-titanium
- •Patients with uncorrected bleeding disorders
- •Female patient with child bearing potential not taking adequate contraceptives or currently breastfeeding
- •Life expectancy of less than twelve months
- •Any planned surgical intervention/procedure within 30 days of the study procedure
- •Any patient considered to be hemodynamically unstable at onset of procedure
- •Patient is currently participating in another investigational drug or device study that has not completed the entire follow up period.
结局指标
主要结局
Primary patency defined as a target lesion without a hemodynamically significant stenosis on duplex ultrasound (>50%, systolic velocity ratio no greater than 2.0) and without TLR
时间窗: 12 months
次要结局
- Technical success, defined as the ability to achieve final residual angiographic stenosis no greater than 30%(Procedure)
- Primary patency rate at different follow-up times defined as absence of hemodynamically significant stenosis at the target area on duplex ultrasound (>50%, systolic velocity ratio no greater than 2.0) and without prior TLR.(1, 6 & 24 months)
- 3) Clinical success at follow-up is defined as an improvement of Rutherford classification at different follow-ups of one class or more as compared to the pre-procedure Rutherford classification.(1, 6, 12 & 24 months)
- Serious adverse events(1, 6, 12, 24 months)
研究者
研究点 (9)
Loading locations...
相似试验
已完成
不适用
Misago Iliac StudyVascular LesionsNCT01016275Flanders Medical Research Program100
已完成
4 期
Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen™ in Subjects With Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2NCT01704378Novo Nordisk A/S89
Unknown
4 期
Golimumab Dried Blood Spot AnalysisUlcerative ColitisNCT02910375Universitaire Ziekenhuizen KU Leuven10
已完成
4 期
Acetazolamide in Decompensated Heart Failure With Volume OveRload (ADVOR)Volume OverloadAcute Decompensated Heart FailureNCT03505788Ziekenhuis Oost-Limburg519
终止
3 期
A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)Systemic Lupus ErythematosusNCT03843125Eli Lilly and Company1,147